WASHINGTON, March 26 -- The U.S. Department of Health and Human Services Food and Drug Administration has issued a notice, published in the Federal Register on March 26, 2024, entitled "Clovis Oncology, Inc., AstraZeneca Pharmaceuticals LP, and GlaxoSmithKline LLC; Withdrawal of Approval of the Indications for Advanced Ovarian Cancer for Poly (ADP-Ribose) Polymerase Inhibitors RUBRACA (Rucaparib) Tablets, LYNPARZA (Olaparib) Tablets, and ZEJULA (Niraparib) Capsules." The notice was issued by La  more

WASHINGTON, March 26 -- The U.S. Department of Health and Human Services Food and Drug Administration has issued a notice, published in the Federal Register on March 26, 2024, entitled "AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of New Drug Application for LYNPARZA (Olaparib) Capsules." The notice was issued by Lauren K. Roth, Associate Commissioner for Policy. * * * SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) fo  more

CONCORD, New Hampshire, March 22 -- The New Hampshire Public Utilities Commission issued the following letter (No. DG 24-042): * * * Re: Liberty Utilities (EnergyNorth Natural Gas) Corp. d/b/a Liberty-Keene Division Summer 2024 Cost of Gas, Hearing Guidelines To the Parties: To facilitate the hearing scheduled in this matter, the Presiding Officer has adopted the following procedures. All participants will be expected to appear in person at the hearing, unless a written request for a particu  more